Top Markets
Coin of the day
Imunon, Inc. Imunon, Inc.

Imunon, Inc.

CLSN
Rank in Stocks #35102
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
Share Price
$1.96
Last synced: 2022-09-20
Market Cap
$4.46M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Imunon, Inc. (CLSN)

Category

Operating Margin for Imunon, Inc. (CLSN)
Operating Margin as of 2026 TTM: 0.00%
According to Imunon, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Imunon, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
0.00% -
CH
0.00% -
KR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.